Oppenheimer Lowers Crescent Capital BDC (NASDAQ:CCAP) Price Target to $19.00

Crescent Capital BDC (NASDAQ:CCAP) had its price objective cut by stock analysts at Oppenheimer from $20.00 to $19.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 39.96% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Wells Fargo & Company lowered their target price on shares of Crescent Capital BDC from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Friday. LADENBURG THALM/SH SH upgraded Crescent Capital BDC to a “strong-buy” rating in a research report on Friday, August 15th. Keefe, Bruyette & Woods decreased their target price on shares of Crescent Capital BDC from $17.00 to $15.50 and set an “outperform” rating on the stock in a research report on Friday. Finally, Zacks Research downgraded shares of Crescent Capital BDC from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Crescent Capital BDC presently has a consensus rating of “Moderate Buy” and an average target price of $16.38.

Crescent Capital BDC Stock Performance

Shares of NASDAQ:CCAP traded down $0.02 during midday trading on Friday, hitting $13.58. 155,996 shares of the stock were exchanged, compared to its average volume of 193,801. The business’s 50-day moving average price is $14.55 and its 200 day moving average price is $14.86. Crescent Capital BDC has a 12 month low of $13.30 and a 12 month high of $20.19. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.27 and a current ratio of 1.27.

Crescent Capital BDC (NASDAQ:CCAP) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.01). Crescent Capital BDC had a net margin of 20.84% and a return on equity of 9.71%. The firm had revenue of $41.35 million during the quarter, compared to analysts’ expectations of $42.35 million. On average, analysts forecast that Crescent Capital BDC will post 2.09 earnings per share for the current year.

Insider Transactions at Crescent Capital BDC

In other news, Director Raymond Barrios bought 3,245 shares of the stock in a transaction on Monday, August 25th. The shares were bought at an average price of $15.63 per share, with a total value of $50,719.35. Following the completion of the acquisition, the director owned 19,177 shares of the company’s stock, valued at approximately $299,736.51. This trade represents a 20.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Catalyst Capital Advisors LLC acquired a new position in Crescent Capital BDC in the second quarter valued at $69,000. Westbourne Investments Inc. purchased a new stake in shares of Crescent Capital BDC in the third quarter worth about $141,000. XTX Topco Ltd purchased a new stake in shares of Crescent Capital BDC during the 2nd quarter valued at about $165,000. Catalina Capital Group LLC purchased a new position in Crescent Capital BDC in the 2nd quarter worth approximately $174,000. Finally, Seven Mile Advisory acquired a new stake in Crescent Capital BDC in the third quarter valued at approximately $189,000. 49.46% of the stock is owned by hedge funds and other institutional investors.

About Crescent Capital BDC

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.